Carly Helfand

Carly Helfand
Carly Helfand
Senior Editor

Carly Helfand is a news editor with FierceMarkets' Life Sciences group, writing for FierceVaccines, FiercePharma and FiercePharmaMarketing. Carly got her start covering pharma while earning her master's at Northwestern University's Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post's Wonkblog and Cape Town's Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at [email protected]

Stories by Carly Helfand

Alere rethinks BBI IPO

So much for those IPO plans. Alere last week decided against taking its BBI Diagnostics businesses public on the London Stock Exchange, citing equity market conditions in the U.K.

NanoString grabs $55M in follow-on offering

NanoString Technologies has big plans going forward, and it's now got some extra funding to make those happen. The company has priced its follow-on offering at $55 million, which should give it a boost as it looks to follow up on last quarter's explosive growth.